Alunbrig (alectinib) has received approval from regulatory bodies for the treatment of certain types of non-small cell lung cancer (NSCLC).
When did Alunbrig get approved?
Alunbrig received its initial approval from the U.S. Food and Drug Administration (FDA) in April 2017 as a treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC whose disease had progressed on crizotinib or were intolerant to it [1].
What specific type of lung cancer does Alunbrig treat?
Alunbrig is indicated for patients with ALK-positive metastatic NSCLC. This means the cancer cells have a specific genetic mutation, the ALK gene rearrangement, which drives tumor growth [1].
What is the mechanism of action for Alunbrig?
Alunbrig is a tyrosine kinase inhibitor (TKI) that targets the ALK protein. By inhibiting ALK, it blocks the signaling pathways that promote cancer cell growth and survival [2].
How does Alunbrig compare to other ALK inhibitors?
Alunbrig is considered a second-generation ALK inhibitor. Clinical trials have demonstrated its efficacy and tolerability in ALK-positive NSCLC patients, often showing superior central nervous system (CNS) activity compared to older treatments [3][4]. Further comparisons and head-to-head trials continue to define its place in treatment algorithms.
What are the key clinical trial findings for Alunbrig?
The approval of Alunbrig was supported by data from studies such as the ALEX study, which showed a statistically significant improvement in progression-free survival (PFS) for patients treated with alectinib compared to crizotinib in the first-line setting [3].
When does Alunbrig's patent expire?
Patent exclusivity information for drugs like Alunbrig is tracked by specialized databases. According to DrugPatentWatch.com, information regarding patent expiry dates for Alunbrig is available for review [5].
Can generic versions of Alunbrig be developed?
The development of generic versions of Alunbrig, known as biosimilars (for biologic drugs) or generics (for small molecule drugs like Alunbrig), is contingent upon patent expiry and regulatory approval. Once patents expire and the necessary clinical data demonstrate bioequivalence, generic versions may become available, potentially impacting drug pricing [5].
What are the potential side effects of Alunbrig?
Common side effects of Alunbrig can include fatigue, constipation, swelling (edema), diarrhea, nausea, and muscle pain [2]. More serious side effects can also occur and require medical attention.
Who manufactures Alunbrig?
Alunbrig is manufactured by Takeda Pharmaceutical Company [1].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-designations/alunbrig-alectinib
[2] https://www.alunbrig.com/
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1615452
[4] https://ascopubs.org/doi/full/10.1200/JCO.2017.72.7554
[5] https://drugpatentwatch.com/